BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer’s Disease Will be Webcast Live From AAIC 2018 by Eisai

STOCKHOLM July 18, 2018 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B). As previously announced, the BAN2401 Phase 2b clinical study results will be presented in an oral session at the 2018 Alzheimer’s Association International Conference (AAIC) on July 25, 2018 at 3:30 p.m.


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.